The patient’s tumor harbored a sole alteration in CDKN2A/B and demonstrated a response with single-agent palbociclib (30% regression; partial response by RECIST 1.1; tumor marker, CA 125, 328 [baseline] down to 50 U/ml [reference range, 0–34 U/ml], PFS, 8.0 months) (Figure 4A and Supplemental Table 1). The gene discussed is CDKN2A; the disease is neoplasm.